                </a></li></ul></div><p><strong>Figure 7.  <span>HLA-A*0201-tetramer screening of EBV reactive donors.</span></strong></p><a id="article1.body1.sec2.sec7.fig1.caption1.p1" name="article1.body1.sec2.sec7.fig1.caption1.p1"></a><p>PBMC from four healthy donors were each re-stimulated for 8 day with three different EBV peptides, LMP1<sub>125–133</sub>, LMP2<sub>356–364</sub>, or LMP2<sub>416–424</sub>, and stained with both HLA-A*0201-LMP1<sub>125–133</sub> (top panel, HLA-A*0201-LMP2<sub>356–364</sub> (middle panel) and HLA-A*0201-LMP2<sub>416–424</sub> tetramers (bottom panel). The dot plot shows gated CD8 T cells and the percentage of tetramer labeled CD8 T cells are given in the upper right quadrant of each plot.</p>
